Literature DB >> 27913677

PHLPPing through history: a decade in the life of PHLPP phosphatases.

Agnieszka T Grzechnik1, Alexandra C Newton2.   

Abstract

In the decade since their discovery, the PH domain leucine-rich repeat protein phosphatases (PHLPP) have emerged as critical regulators of cellular homeostasis, and their dysregulation is associated with various pathophysiologies, ranging from cancer to degenerative diseases, such as diabetes and heart disease. The two PHLPP isozymes, PHLPP1 and PHLPP2, were identified in a search for phosphatases that dephosphorylate Akt, and thus suppress growth factor signaling. However, given that there are over 200 000 phosphorylated residues in a single cell, and fewer than 50 Ser/Thr protein phosphatases, it is not surprising that PHLPP has many other cellular functions yet to be discovered, including a recently identified role in regulating the epigenome. Both PHLPP1 and PHLPP2 are commonly deleted in human cancers, supporting a tumor suppressive role. Conversely, the levels of one isozyme, PHLPP1, are elevated in diabetes. Thus, mechanisms to correctly control PHLPP activity in cells are critical for normal cellular homeostasis. This review summarizes the known functions of PHLPP and its role in disease.
© 2016 The Author(s); published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  PHLPP1; PHLPP2; PP2C; phosphatase; protein kinase B; tumor suppressor

Mesh:

Substances:

Year:  2016        PMID: 27913677      PMCID: PMC5783572          DOI: 10.1042/BST20160170

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  57 in total

1.  Pharmacological inhibition of pleckstrin homology domain leucine-rich repeat protein phosphatase is neuroprotective: differential effects on astrocytes.

Authors:  Travis C Jackson; Jonathan D Verrier; Tomas Drabek; Keri Janesko-Feldman; Delbert G Gillespie; Thomas Uray; Cameron Dezfulian; Robert S Clark; Hülya Bayir; Edwin K Jackson; Patrick M Kochanek
Journal:  J Pharmacol Exp Ther       Date:  2013-09-10       Impact factor: 4.030

Review 2.  Turning off AKT: PHLPP as a drug target.

Authors:  Alexandra C Newton; Lloyd C Trotman
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

3.  PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation and cell growth.

Authors:  Jianyu Liu; Payton D Stevens; Xin Li; Micheal D Schmidt; Tianyan Gao
Journal:  Mol Cell Biol       Date:  2011-10-10       Impact factor: 4.272

4.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth.

Authors:  Tianyan Gao; Frank Furnari; Alexandra C Newton
Journal:  Mol Cell       Date:  2005-04-01       Impact factor: 17.970

5.  Isoform-specific defects of insulin stimulation of Akt/protein kinase B (PKB) in skeletal muscle cells from type 2 diabetic patients.

Authors:  D Cozzone; S Fröjdö; E Disse; C Debard; M Laville; L Pirola; H Vidal
Journal:  Diabetologia       Date:  2008-01-18       Impact factor: 10.122

6.  Defining the human deubiquitinating enzyme interaction landscape.

Authors:  Mathew E Sowa; Eric J Bennett; Steven P Gygi; J Wade Harper
Journal:  Cell       Date:  2009-07-16       Impact factor: 41.582

7.  Phlpp1 facilitates post-traumatic osteoarthritis and is induced by inflammation and promoter demethylation in human osteoarthritis.

Authors:  E W Bradley; L R Carpio; M E McGee-Lawrence; C Castillejo Becerra; D F Amanatullah; L E Ta; M Otero; M B Goldring; S Kakar; J J Westendorf
Journal:  Osteoarthritis Cartilage       Date:  2015-12-31       Impact factor: 6.576

8.  Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer.

Authors:  Kang Su Cho; Joong Shik Lee; Nam Hoon Cho; Kyeongmee Park; Won Sik Ham; Young Deuk Choi
Journal:  Prostate       Date:  2008-06-01       Impact factor: 4.104

9.  Deletion of the PH-domain and Leucine-rich Repeat Protein Phosphatase 1 (Phlpp1) Increases Fibroblast Growth Factor (Fgf) 18 Expression and Promotes Chondrocyte Proliferation.

Authors:  Elizabeth W Bradley; Lomeli R Carpio; Alexandra C Newton; Jennifer J Westendorf
Journal:  J Biol Chem       Date:  2015-05-07       Impact factor: 5.157

10.  Greatwall promotes cell transformation by hyperactivating AKT in human malignancies.

Authors:  Jorge Vera; Lydia Lartigue; Suzanne Vigneron; Gilles Gadea; Veronique Gire; Maguy Del Rio; Isabelle Soubeyran; Frederic Chibon; Thierry Lorca; Anna Castro
Journal:  Elife       Date:  2015-11-27       Impact factor: 8.140

View more
  35 in total

1.  Cannabinoid-1 Receptor Antagonism Improves Glycemic Control and Increases Energy Expenditure Through Sirtuin-1/Mechanistic Target of Rapamycin Complex 2 and 5'Adenosine Monophosphate-Activated Protein Kinase Signaling.

Authors:  Jie Liu; Grzegorz Godlewski; Tony Jourdan; Ziyi Liu; Resat Cinar; Keming Xiong; George Kunos
Journal:  Hepatology       Date:  2019-03-06       Impact factor: 17.425

2.  PH domain leucine-rich repeat protein phosphatase 2 (PHLPP2) regulates G-protein-coupled receptor kinase 5 (GRK5)-induced cardiac hypertrophy in vitro.

Authors:  Szu-Tsen Yeh; Cristina M Zambrano; Walter J Koch; Nicole H Purcell
Journal:  J Biol Chem       Date:  2018-04-08       Impact factor: 5.157

3.  Deficiency in the phosphatase PHLPP1 suppresses osteoclast-mediated bone resorption and enhances bone formation in mice.

Authors:  Anna M Mattson; Dana L Begun; David H H Molstad; Margaret A Meyer; Merry Jo Oursler; Jennifer J Westendorf; Elizabeth W Bradley
Journal:  J Biol Chem       Date:  2019-06-12       Impact factor: 5.157

4.  PHLPP1/Nrf2-Mdm2 axis induces renal apoptosis via influencing nucleo-cytoplasmic shuttling of FoxO1 during diabetic nephropathy.

Authors:  Alpana Mathur; Vivek Kumar Pandey; Mohammad Fareed Khan; Poonam Kakkar
Journal:  Mol Cell Biochem       Date:  2021-05-31       Impact factor: 3.396

5.  Phlpp inhibitors block pain and cartilage degradation associated with osteoarthritis.

Authors:  Soyun M Hwang; Marina Feigenson; Dana L Begun; Lomeli Carpio Shull; Kirsty L Culley; Miguel Otero; Mary B Goldring; Lauren E Ta; Sanjeev Kakar; Elizabeth W Bradley; Jennifer J Westendorf
Journal:  J Orthop Res       Date:  2017-11-28       Impact factor: 3.494

6.  BRAP-2 promotes DNA damage induced germline apoptosis in C. elegans through the regulation of SKN-1 and AKT-1.

Authors:  Dayana R D'Amora; Queenie Hu; Monica Pizzardi; Terrance J Kubiseski
Journal:  Cell Death Differ       Date:  2018-01-22       Impact factor: 15.828

Review 7.  PHLPPing the balance: restoration of protein kinase C in cancer.

Authors:  Hannah Tovell; Alexandra C Newton
Journal:  Biochem J       Date:  2021-01-29       Impact factor: 3.857

Review 8.  The impact of phosphatases on proliferative and survival signaling in cancer.

Authors:  Goutham Narla; Jaya Sangodkar; Christopher B Ryder
Journal:  Cell Mol Life Sci       Date:  2018-05-03       Impact factor: 9.261

9.  Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.

Authors:  KyeongJin Kim; Dongryeol Ryu; Paola Dongiovanni; Lale Ozcan; Shruti Nayak; Beatrix Ueberheide; Luca Valenti; Johan Auwerx; Utpal B Pajvani
Journal:  Gastroenterology       Date:  2017-08-30       Impact factor: 22.682

10.  DNA methylation and FoxO3a regulate PHLPP1 expression in chondrocytes.

Authors:  Clara M Castillejo Becerra; Anna M Mattson; David H H Molstad; Ian M Lorang; Jennifer J Westendorf; Elizabeth W Bradley
Journal:  J Cell Biochem       Date:  2018-05-18       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.